Loading...
Loading...

Go to the content (press return)

A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV

Author
Negredo, E.; Perez, N.; Clotet, B.
Type of activity
Journal article
Journal
PloS one
Date of publication
2020-09-17
Volume
15
Number
9
First page
1
Last page
15
DOI
10.1371/journal.pone.0238575
Repository
http://hdl.handle.net/2117/343162 Open in new window
URL
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0238575 Open in new window
Abstract
Objective Optimization of antiretroviral therapy and anti-inflammatory treatments, such as statins, are among the strategies aimed at reducing metabolic disorders, inflammation and immune activation in people living with HIV (PLWH). We evaluated the potential benefit of combining both strategies. Design Forty-two PLWH aged =40 years receiving a protease inhibitor (PI)-based regimen were randomized (1:1) to switch from PI to Raltegravir (n = 20), or to remain on PI (n = 22). After 24 weeks, al...
Citation
Negredo, E.; Perez, N.; Clotet, B. A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. "PloS one", 17 Setembre 2020, vol. 15, núm. 9, p. 1-15.
Group of research
GRBIO - Biostatistics and Bioinformatics Research Group

Participants

  • Negredo Puigmal, Eugènia  (author)
  • Perez Alvarez, Nuria  (author)
  • Clotet Sala, Bonaventura  (author)

Attachments